Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4583911 | 0.98 | TAAR1 (0.58) | TAAR1LTA4HPLA2G2AAPPSMN1; SMN2 | |
| SCHEMBL14870900 | 0.88 | APP (0.50) | TAAR1LTA4HPLA2G2AAPP | |
| SCHEMBL21070896 | 0.87 | TAAR1 (0.47) | TAAR1LTA4HPLA2G2AAPP | |
| SCHEMBL6714503 | 0.87 | TAAR1 (0.75) | TAAR1LTA4HPLA2G2ASMN1; SMN2ESR1 | |
| Hydrochloric Acid SCHEMBL7123193 | 0.86 | APP (0.48) | TAAR1LTA4HPLA2G2AAPP | |
| SCHEMBL19001642 | 0.86 | APP (0.48) | TAAR1APP | |
| SCHEMBL10458288 | 0.81 | APP (0.52) | APPALDH1A1 | |
| SCHEMBL24016966 | 0.80 | APP (0.56) | APP | |
| SCHEMBL30073067 | 0.80 | APP (0.56) | APP | |
| SCHEMBL29237868 | 0.80 | TAAR1 (0.65) | TAAR1LTA4HPLA2G2ASMN1; SMN2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544967-B1 | SALTS OF INDAZOLE DERIVATIVE AND CRYSTALS THEREOF | EISAI R&D MAN CO LTD (JP) | 2023-06-28 | — | — | EP | disclosed |
| EP-3544967-B1 | SALTS OF INDAZOLE DERIVATIVE AND CRYSTALS THEREOF | EISAI R&D MAN CO LTD (JP) | 2023-06-28 | — | — | EP | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| EP-3889133-A1 | ESTROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-113024466-A | Tetra-substituted olefin compound and use thereof | 卫材 R&D 管理有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-109790141-B | Salts of indazole derivatives and crystals thereof | 卫材 R&D 管理有限公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-107847498-B | Tetra-substituted olefin compound and use thereof | 卫材R&D管理有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| WO-2000034261-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5674863-A | BENZODIAZEPINEDIONE DERIVATIVE; FIBRINOGIN BINDING INHIBITOR | GENENTECH, INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5674865-A | BENZODIAZEPINEDIONE DERIVATIVE; FIBRINOGIN BINDING INHIBITOR | GENENTECH, INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663166-A | ANTICOAGULANTS OF 1,4-BENZODIAZEPINE-2,5-DIONE AND 2-BENZOAZEPINE-1,4-DIONE DERIVATIVES; PREVENTS FIBRINOGEN BINDING NECESSARY FOR PLATELET AGGREGATION; SIDE EFFECT REDUCTION, E.G. EXCESSIVE BLEEDING | GENENTECH, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5565449-A | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0610334-B1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII B III A RECEPTOR | GENENTECH INC (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5403836-A | Anticoagulants | GENENTECH, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0610334-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPII b?III a? RECEPTOR. | GENENTECH INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5250679-A | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor | GENENTECH, INC. (US) | 1993-10-05 | — | — | US | disclosed |
| WO-1993008174-A1 | NONPEPTIDYL INTEGRIN INHIBITORS HAVING SPECIFICITY FOR THE GPIIbIIIa RECEPTOR | GENENTECH, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | BRCA1, ESR2, ESR1 | TAAR1 4179/4885LTA4H 4278/4885PLA2G2A 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.